References
1. Di Virgilio F, Boeynaems JM, Robson SC. Extracellular nucleotides as
negative modulators of immunity. Curr Opin Pharmacol 2009; 9:507-13.
2. Burnstock G, Knight GE. Cellular distribution and functions of P2
receptor subtypes in different systems. Int Rev Cytol 2004; 240:31-304.
3. Pelleg A, Schulman ES, Barnes PJ. Adenosine 5’-triphosphate’s role in
bradycardia and syncope associated with pulmonary embolism. Respir Res
2018; 19:142.
4. Burnstock G. Purinergic signaling and vascular cell proliferation and
death. Arterioscler Thromb Vasc Biol 2002; 22:364-73.
5. Chen Y, Corriden R, Inoue Y, et al. ATP release guides neutrophil
chemotaxis via P2Y2 and A3 receptors. Science 2006; 314:1792-5.
6. Kronlage M, Song J, Sorokin L, et al. Autocrine purinergic receptor
signaling is essential for macrophage chemotaxis. Sci Signal 2010;
3:ra55.
7. Axtell RA, Sandborg RR, Smolen JE, et al. Exposure of human
neutrophils to exogenous nucleotides causes elevation in intracellular
calcium, transmembrane calcium fluxes, and an alteration of a cytosolic
factor resulting in enhanced superoxide production in response to FMLP
and arachidonic acid. Blood 1990; 75:1324-32.
8. Iwata M, Ota KT, Li XY, et al. Psychological Stress Activates the
Inflammasome via Release of Adenosine Triphosphate and Stimulation of
the Purinergic Type 2X7 Receptor. Biol Psychiatry 2016; 80:12-22.
9. Horenstein AL, Chillemi A, Zaccarello G, et al. A CD38/CD203a/CD73
ectoenzymatic pathway independent of CD39 drives a novel adenosinergic
loop in human T lymphocytes. Oncoimmunology 2013; 2:e26246.
10. Horenstein AL, Chillemi A, Quarona V, et al. NAD(+)-Metabolizing
Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma
Model. Cells 2015; 4:520-37.
11. Chen L, Diao L, Yang Y, et al. CD38-Mediated Immunosuppression as a
Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov
2018; 8:1156-1175.
12. Vaisitti T, Audrito V, Serra S, et al. NAD+-metabolizing
ecto-enzymes shape tumor-host interactions: the chronic lymphocytic
leukemia model. FEBS Lett 2011; 585:1514-20.
13. Fredholm BB, AP IJ, Jacobson KA, et al. International Union of Basic
and Clinical Pharmacology. LXXXI. Nomenclature and classification of
adenosine receptors–an update. Pharmacol Rev 2011; 63:1-34.
14. Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive
adenosine in cancer. Nat Rev Cancer 2017; 17:709-724.
15. Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets.
Nature reviews. Drug discovery 2006; 5:247-264.
16. Cronstein BN, Levin RI, Philips M, et al. Neutrophil adherence to
endothelium is enhanced via adenosine A1 receptors and inhibited via
adenosine A2 receptors. J Immunol 1992; 148:2201-6.
17. Vecchio EA, Tan CY, Gregory KJ, et al. Ligand-Independent Adenosine
A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell
Proliferation. J Pharmacol Exp Ther 2016; 357:36-44.
18. Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects
tumors from antitumor T cells. Proc Natl Acad Sci U S A 2006;
103:13132-7.
19. Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities
of adenosine in cancer. Curr Opin Pharmacol 2016; 29:7-16.
20. Stockwell J, Jakova E, Cayabyab FS. Adenosine A1 and A2A Receptors
in the Brain: Current Research and Their Role in Neurodegeneration.
Molecules 2017; 22.
21. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of
antitumor immune responses. Trends Immunol 2012; 33:231-7.
22. Regateiro FS, Howie D, Nolan KF, et al. Generation of
anti-inflammatory adenosine by leukocytes is regulated by TGF-beta. Eur
J Immunol 2011; 41:2955-65.
23. Deaglio S, Robson SC. Ectonucleotidases as regulators of purinergic
signaling in thrombosis, inflammation, and immunity. Adv Pharmacol 2011;
61:301-32.
24. Eltzschig HK, Kohler D, Eckle T, et al. Central role of
Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009;
113:224-32.
25. Dwyer KM, Hanidziar D, Putheti P, et al. Expression of CD39 by human
peripheral blood CD4+ CD25+ T cells denotes a regulatory memory
phenotype. Am J Transplant 2010; 10:2410-20.
26. Fang F, Yu M, Cavanagh MM, et al. Expression of CD39 on Activated T
Cells Impairs their Survival in Older Individuals. Cell Rep 2016;
14:1218-1231.
27. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by
CD39 and CD73 expressed on regulatory T cells mediates immune
suppression. J Exp Med 2007; 204:1257-65.
28. Mascanfroni ID, Takenaka MC, Yeste A, et al. Metabolic control of
type 1 regulatory T cell differentiation by AHR and HIF1-α. Nature
Medicine 2015; 21.
29. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of
functional human regulatory T cells (Treg) from the peripheral blood
based on the CD39 expression. J Immunol Methods 2009; 346:55-63.
30. Ye L, Goodall JC, Zhang L, et al. TCR usage, gene expression and
function of two distinct FOXP3(+)Treg subsets within CD4(+)CD25(hi) T
cells identified by expression of CD39 and CD45RO. Immunol Cell Biol
2016; 94:293-305.
31. Lu Y, Wang X, Gu J, et al. iTreg induced from CD39(+) naive T cells
demonstrate enhanced proliferate and suppressive ability. Int
Immunopharmacol 2015; 28:925-30.
32. Zhang X, Ouyang X, Xu Z, et al. CD8+CD103+ iTregs Inhibit Chronic
Graft-versus-Host Disease with Lupus Nephritis by the Increased
Expression of CD39. Mol Ther 2019; 27:1963-1973.
33. Gu J, Ni X, Pan X, et al. Human CD39(hi) regulatory T cells present
stronger stability and function under inflammatory conditions. Cell Mol
Immunol 2017; 14:521-528.
34. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of
ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular
ATP and immune suppression. Blood 2007; 110:1225-32.
35. Hu G, Wu P, Pu C, et al. Tumor-infiltrating CD39+ γδTregs are novel
immunosuppressive T cells in human colorectal cancer. Oncoimmunology
2017; 6:-.
36. Plitas G, Rudensky AY. Regulatory T Cells: Differentiation and
Function. Cancer Immunol Res 2016; 4:721-5.
37. Ahlmanner F, Sundström P, Akeus P, et al. CD39(+) regulatory T cells
accumulate in colon adenocarcinomas and display markers of increased
suppressive function. Oncotarget 2018; 9:36993-37007.
38. Zhou Q, Yan J, Putheti P, et al. Isolated CD39 expression on CD4+ T
cells denotes both regulatory and memory populations. Am J Transplant
2009; 9:2303-11.
39. Thelen M, Lechner A, Wennhold K, et al. CD39 Expression Defines Cell
Exhaustion in Tumor-Infiltrating CD8(+) T Cells-Letter. Cancer Res 2018;
78:5173-5174.
40. Canale FP, Ramello MC, Nunez N, et al. CD39 Expression Defines Cell
Exhaustion in Tumor-Infiltrating CD8(+) T Cells. Cancer Res 2018;
78:115-128.
41. Duhen T, Duhen R, Montler R, et al. Co-expression of CD39 and CD103
identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun
2018; 9:2724.
42. Bai A, Moss A, Rothweiler S, et al. NADH oxidase-dependent CD39
expression by CD8(+) T cells modulates interferon gamma responses via
generation of adenosine. Nat Commun 2015; 6:8819.
43. Bai A, Robson S. Beyond ecto-nucleotidase: CD39 defines human Th17
cells with CD161. Purinergic Signal 2015; 11:317-9.
44. Chalmin F, Mignot G, Bruchard M, et al. Stat3 and Gfi-1
transcription factors control Th17 cell immunosuppressive activity via
the regulation of ectonucleotidase expression. Immunity 2012; 36:362-73.
45. Fernandez D, Flores-Santibanez F, Neira J, et al. Purinergic
Signaling as a Regulator of Th17 Cell Plasticity. PLoS One 2016;
11:e0157889.
46. Liberal R, Grant CR, Ma Y, et al. CD39 mediated regulation of
Th17-cell effector function is impaired in juvenile autoimmune liver
disease. J Autoimmun 2016; 72:102-12.
47. Lin R, Zhang H, Yuan Y, et al. Fatty Acid Oxidation Controls CD8(+)
Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma. Cancer
Immunol Res 2020; 8:479-492.
48. Otsuka A, Hanakawa S, Miyachi Y, Kabashima K. CD39: a new surface
marker of mouse regulatory γδ T cells. J Allergy Clin Immunol 2013;
132:1448-51.
49. Kaku H, Cheng KF, Al-Abed Y, Rothstein TL. A novel mechanism of B
cell-mediated immune suppression through CD73 expression and adenosine
production. J Immunol 2014; 193:5904-13.
50. Figueiro F, Muller L, Funk S, et al. Phenotypic and functional
characteristics of CD39(high) human regulatory B cells (Breg).
Oncoimmunology 2016; 5:e1082703.
51. Saze Z, Schuler PJ, Hong CS, et al. Adenosine production by human B
cells and B cell-mediated suppression of activated T cells. Blood 2013;
122:9-18.
52. Dwyer KM, Deaglio S, Gao W, et al. CD39 and control of cellular
immune responses. Purinergic Signal 2007; 3:171-80.
53. Jacob F, Perez Novo C, Bachert C, Van Crombruggen K. Purinergic
signaling in inflammatory cells: P2 receptor expression, functional
effects, and modulation of inflammatory responses. Purinergic Signal
2013; 9:285-306.
54. Przybyla T, Sakowicz-Burkiewicz M, Pawelczyk T. Purinergic signaling
in B cells. Acta Biochim Pol 2018; 65:1-7.
55. Sakowicz-Burkiewicz M, Kocbuch K, Grden M, et al. High glucose
concentration impairs ATP outflow and immunoglobulin production by human
peripheral B lymphocytes: involvement of P2X7 receptor. Immunobiology
2013; 218:591-601.
56. Pulte ED, Broekman MJ, Olson KE, et al. CD39/NTPDase-1 activity and
expression in normal leukocytes. Thromb Res 2007; 121:309-17.
57. Flogel U, Burghoff S, van Lent PL, et al. Selective activation of
adenosine A2A receptors on immune cells by a CD73-dependent prodrug
suppresses joint inflammation in experimental rheumatoid arthritis. Sci
Transl Med 2012; 4:146ra108.
58. Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by
adenosine. Arterioscler Thromb Vasc Biol 2012; 32:856-64.
59. Eltzschig HK, Eckle T, Mager A, et al. ATP release from activated
neutrophils occurs via connexin 43 and modulates adenosine-dependent
endothelial cell function. Circ Res 2006; 99:1100-8.
60. Eltzschig HK, Thompson LF, Karhausen J, et al. Endogenous adenosine
produced during hypoxia attenuates neutrophil accumulation: coordination
by extracellular nucleotide metabolism. Blood 2004; 104:3986-92.
61. Corriden R, Chen Y, Inoue Y, et al. Ecto-nucleoside triphosphate
diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis
by hydrolyzing released ATP to adenosine. J Biol Chem 2008; 283:28480-6.
62. Eltzschig HK, Weissmuller T, Mager A, Eckle T. Nucleotide metabolism
and cell-cell interactions. Methods Mol Biol 2006; 341:73-87.
63. Shah D, Romero F, Stafstrom W, et al. Extracellular ATP mediates the
late phase of neutrophil recruitment to the lung in murine models of
acute lung injury. Am J Physiol Lung Cell Mol Physiol 2014; 306:L152-61.
64. Allard D, Allard B, Stagg J. On the mechanism of anti-CD39 immune
checkpoint therapy. J Immunother Cancer 2020; 8.
65. Inoue Y, Chen Y, Hirsh MI, et al. A3 and P2Y2 receptors control the
recruitment of neutrophils to the lungs in a mouse model of sepsis.
Shock 2008; 30:173-7.
66. Reutershan J, Vollmer I, Stark S, et al. Adenosine and inflammation:
CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into
the lungs. FASEB J 2009; 23:473-82.
67. Beldi G, Banz Y, Kroemer A, et al. Deletion of CD39 on natural
killer cells attenuates hepatic ischemia/reperfusion injury in mice.
Hepatology 2010; 51:1702-11.
68. Morandi F, Horenstein AL, Chillemi A, et al. CD56brightCD16- NK
Cells Produce Adenosine through a CD38-Mediated Pathway and Act as
Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. J
Immunol 2015; 195:965-72.
69. Beldi G, Wu Y, Banz Y, et al. Natural killer T cell dysfunction in
CD39-null mice protects against concanavalin A-induced hepatitis.
Hepatology 2008; 48:841-52.
70. Nowak-Machen M, Schmelzle M, Hanidziar D, et al. Pulmonary natural
killer T cells play an essential role in mediating hyperoxic acute lung
injury. Am J Respir Cell Mol Biol 2013; 48:601-9.
71. Seshadri A, Brat GA, Yorkgitis BK, et al. Altered monocyte and NK
cell phenotypes correlate with posttrauma infection. J Trauma Acute Care
Surg 2019; 87:337-341.
72. Zhang H, Vijayan D, Li XY, et al. The role of NK cells and CD39 in
the immunological control of tumor metastases. Oncoimmunology 2019;
8:e1593809.
73. Yan J, Li XY, Roman Aguilera A, et al. Control of Metastases via
Myeloid CD39 and NK Cell Effector Function. Cancer Immunol Res 2020;
8:356-367.
74. Berchtold S, Ogilvie AL, Bogdan C, et al. Human monocyte derived
dendritic cells express functional P2X and P2Y receptors as well as
ecto-nucleotidases. FEBS Lett 1999; 458:424-8.
75. Mizumoto N, Kumamoto T, Robson SC, et al. CD39 is the dominant
Langerhans cell-associated ecto-NTPDase: modulatory roles in
inflammation and immune responsiveness. Nat Med 2002; 8:358-65.
76. Cobbold SP, Adams E, Nolan KF, et al. Connecting the mechanisms of
T-cell regulation: dendritic cells as the missing link. Immunol Rev
2010; 236:203-18.
77. Burch LH, Picher M. E-NTPDases in human airways: Regulation and
relevance for chronic lung diseases. Purinergic Signal 2006; 2:399-408.
78. Yoshida O, Kimura S, Jackson EK, et al. CD39 expression by hepatic
myeloid dendritic cells attenuates inflammation in liver transplant
ischemia-reperfusion injury in mice. Hepatology 2013; 58:2163-75.
79. Mascanfroni ID, Yeste A, Vieira SM, et al. IL-27 acts on DCs to
suppress the T cell response and autoimmunity by inducing expression of
the immunoregulatory molecule CD39. Nat Immunol 2013; 14:1054-63.
80. Zhao R, Qiao J, Zhang X, et al. Toll-Like Receptor-Mediated
Activation of CD39 Internalization in BMDCs Leads to Extracellular ATP
Accumulation and Facilitates P2X7 Receptor Activation. Front Immunol
2019; 10:2524.
81. Ohradanova-Repic A, Machacek C, Charvet C, et al. Extracellular
Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages
and a Novel Target to Treat Diseases With Macrophage Imbalances. Front
Immunol 2018; 9:852.
82. Zanin RF, Braganhol E, Bergamin LS, et al. Differential macrophage
activation alters the expression profile of NTPDase and
ecto-5’-nucleotidase. PLoS One 2012; 7:e31205.
83. Hasko G, Csoka B, Koscso B, et al. Ecto-5’-nucleotidase (CD73)
decreases mortality and organ injury in sepsis. J Immunol 2011;
187:4256-67.
84. Petrovic-Djergovic D, Hyman MC, Ray JJ, et al. Tissue-resident
ecto-5’ nucleotidase (CD73) regulates leukocyte trafficking in the
ischemic brain. J Immunol 2012; 188:2387-98.
85. Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive
immunity. Annu Rev Immunol 2015; 33:291-353.
86. Cohen HB, Briggs KT, Marino JP, et al. TLR stimulation initiates a
CD39-based autoregulatory mechanism that limits macrophage inflammatory
responses. Blood 2013; 122:1935-45.
87. Savio LEB, de Andrade Mello P, Figliuolo VR, et al. CD39 limits P2X7
receptor inflammatory signaling and attenuates sepsis-induced liver
injury. J Hepatol 2017; 67:716-726.
88. Cohen HB, Ward A, Hamidzadeh K, et al. IFN-gamma Prevents Adenosine
Receptor (A2bR) Upregulation To Sustain the Macrophage Activation
Response. J Immunol 2015; 195:3828-37.
89. Levesque SA, Kukulski F, Enjyoji K, et al. NTPDase1 governs
P2X7-dependent functions in murine macrophages. Eur J Immunol 2010;
40:1473-85.
90. Savio LEB, de Andrade Mello P, Santos S, et al. P2X7 receptor
activation increases expression of caveolin-1 and formation of
macrophage lipid rafts, thereby boosting CD39 activity. J Cell Sci 2020;
133.
91. Liao H, Hyman MC, Baek AE, et al. cAMP/CREB-mediated transcriptional
regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39)
expression. J Biol Chem 2010; 285:14791-805.
92. Montalbán Del Barrio I, Penski C, Schlahsa L, et al.
Adenosine-generating ovarian cancer cells attract myeloid cells which
differentiate into adenosine-generating tumor associated macrophages - a
self-amplifying, CD39- and CD73-dependent mechanism for tumor immune
escape. J Immunother Cancer 2016; 4:49.
93. Kanthi YM, Sutton NR, Pinsky DJ. CD39: Interface between vascular
thrombosis and inflammation. Curr Atheroscler Rep 2014; 16:425.
94. Roy C, Tabiasco J, Caillon A, et al. Loss of vascular expression of
nucleoside triphosphate diphosphohydrolase-1/CD39 in hypertension.
Purinergic Signal 2018; 14:73-82.
95. Feng L, Sun X, Csizmadia E, et al. Vascular CD39/ENTPD1 directly
promotes tumor cell growth by scavenging extracellular adenosine
triphosphate. Neoplasia 2011; 13:206-16.
96. Packham MA, Mustard JF. Platelet aggregation and adenosine
diphosphate/adenosine triphosphate receptors: a historical perspective.
Semin Thromb Hemost 2005; 31:129-38.
97. Atkinson B, Dwyer K, Enjyoji K, Robson SC. Ecto-nucleotidases of the
CD39/NTPDase family modulate platelet activation and thrombus formation:
Potential as therapeutic targets. Blood Cells Mol Dis 2006; 36:217-22.
98. Fung CY, Marcus AJ, Broekman MJ, Mahaut-Smith MP. P2X(1) receptor
inhibition and soluble CD39 administration as novel approaches to widen
the cardiovascular therapeutic window. Trends Cardiovasc Med 2009;
19:1-5.
99. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. The endothelial cell
ecto-ADPase responsible for inhibition of platelet function is CD39. J
Clin Invest 1997; 99:1351-60.
100. El-Omar MM, Islam N, Broekman MJ, et al. The ratio of ADP- to
ATP-ectonucleotidase activity is reduced in patients with coronary
artery disease. Thromb Res 2005; 116:199-206.
101. Birk AV, Broekman MJ, Gladek EM, et al. Role of extracellular ATP
metabolism in regulation of platelet reactivity. J Lab Clin Med 2002;
140:166-75.
102. Abraham MK, Nolte A, Reus R, et al. In vitro Study of a Novel Stent
Coating Using Modified CD39 Messenger RNA to Potentially Reduce Stent
Angioplasty-Associated Complications. PLoS One 2015; 10:e0138375.
103. Aho J, Helenius M, Vattulainen-Collanus S, et al. Extracellular ATP
protects endothelial cells against DNA damage. Purinergic Signal 2016;
12:575-81.
104. Castilhos LG, Doleski PH, Adefegha SA, et al. Altered
E-NTPDase/E-ADA activities and CD39 expression in platelets of sickle
cell anemia patients. Biomed Pharmacother 2016; 79:241-6.
105. Pulte D, Olson KE, Broekman MJ, et al. CD39 activity correlates
with stage and inhibits platelet reactivity in chronic lymphocytic
leukemia. J Transl Med 2007; 5:23.
106. Hohmann JD, Peter K. Activated-platelet targeting of CD39 as a
potential way forward. The quest for efficient antithrombotic therapy
without associated bleeding complications. Hamostaseologie 2016;
36:17-25.
107. Yamamoto K, Furuya K, Nakamura M, et al. Visualization of
flow-induced ATP release and triggering of Ca2+ waves at caveolae in
vascular endothelial cells. J Cell Sci 2011; 124:3477-83.
108. Buergler JM, Maliszewski CR, Broekman MJ, et al. Effects of
SolCD39, a novel inhibitor of Platelet Aggregation, on Platelet
Deposition and Aggregation after PTCA in a Porcine Model. J Thromb
Thrombolysis 2005; 19:115-22.
109. Drosopoulos JH, Broekman MJ, Islam N, et al. Site-directed
mutagenesis of human endothelial cell ecto-ADPase/soluble CD39:
requirement of glutamate 174 and serine 218 for enzyme activity and
inhibition of platelet recruitment. Biochemistry 2000; 39:6936-43.
110. Huttinger ZM, Milks MW, Nickoli MS, et al. Ectonucleotide
triphosphate diphosphohydrolase-1 (CD39) mediates resistance to
occlusive arterial thrombus formation after vascular injury in mice. Am
J Pathol 2012; 181:322-33.
111. Anyanwu AC, Kanthi Y, Fukase K, et al. Tuning the
Thromboinflammatory Response to Venous Flow Interruption by the
Ectonucleotidase CD39. Arterioscler Thromb Vasc Biol 2019; 39:e118-e129.
112. Chaurasia SN, Kushwaha G, Pandey A, Dash D. Human platelets express
functional ectonucleotidases that restrict platelet activation
signaling. Biochem Biophys Res Commun 2020; 527:104-109.
113. Enjyoji K, Sevigny J, Lin Y, et al. Targeted disruption of cd39/ATP
diphosphohydrolase results in disordered hemostasis and
thromboregulation. Nat Med 1999; 5:1010-7.
114. Jiang ZG, Wu Y, Csizmadia E, et al. Characterization of circulating
microparticle-associated CD39 family ecto-nucleotidases in human plasma.
Purinergic Signal 2014; 10:611-8.
115. Muller L, Mitsuhashi M, Simms P, et al. Tumor-derived exosomes
regulate expression of immune function-related genes in human T cell
subsets. Sci Rep 2016; 6:20254.
116. Clayton A, Al-Taei S, Webber J, et al. Cancer exosomes express CD39
and CD73, which suppress T cells through adenosine production. J Immunol
2011; 187:676-83.
117. Zhang F, Li R, Yang Y, et al. Specific Decrease in B-Cell-Derived
Extracellular Vesicles Enhances Post-Chemotherapeutic CD8(+) T Cell
Responses. Immunity 2019; 50:738-750 e7.
118. Schuler PJ, Saze Z, Hong CS, et al. Human CD4+ CD39+ regulatory T
cells produce adenosine upon co-expression of surface CD73 or contact
with CD73+ exosomes or CD73+ cells. Clin Exp Immunol 2014; 177:531-43.
119. Schmelzle M, Splith K, Andersen LW, et al. Increased plasma levels
of microparticles expressing CD39 and CD133 in acute liver injury.
Transplantation 2013; 95:63-9.
120. Fan W, Wang W, Wu J, et al. Identification of CD4(+) T-cell-derived
CD161(+) CD39(+) and CD39(+)CD73(+) microparticles as new biomarkers for
rheumatoid arthritis. Biomark Med 2017; 11:107-116.
121. Angioni R, Liboni C, Herkenne S, et al. CD73(+) extracellular
vesicles inhibit angiogenesis through adenosine A2B receptor signalling.
J Extracell Vesicles 2020; 9:1757900.
122. Banz Y, Beldi G, Wu Y, et al. CD39 is incorporated into plasma
microparticles where it maintains functional properties and impacts
endothelial activation. Br J Haematol 2008; 142:627-37.
123. Yang M, Lu L, Kang Z, et al. Overexpressed CD39 mitigates
sepsisinduced kidney epithelial cell injury via suppressing the
activation of NLR family pyrin domain containing 3. Int J Mol Med 2019;
44:1707-1718.
124. Huang H, Xu R, Lin F, et al. High circulating CD39(+) regulatory T
cells predict poor survival for sepsis patients. Int J Infect Dis 2015;
30:57-63.
125. Imai M, Goepfert C, Kaczmarek E, Robson SC. CD39 modulates IL-1
release from activated endothelial cells. Biochem Biophys Res Commun
2000; 270:272-8.
126. Csoka B, Nemeth ZH, Toro G, et al. CD39 improves survival in
microbial sepsis by attenuating systemic inflammation. FASEB J 2015;
29:25-36.
127. Bertoncheli Cde M, Zimmermann CE, Jaques JA, et al. Increased
NTPDase activity in lymphocytes during experimental sepsis.
ScientificWorldJournal 2012; 2012:941906.
128. Bao R, Shui X, Hou J, et al. Adenosine and the adenosine A2A
receptor agonist, CGS21680, upregulate CD39 and CD73 expression through
E2F-1 and CREB in regulatory T cells isolated from septic mice. Int J
Mol Med 2016; 38:969-75.
129. Liu J, Shi K, Chen M, et al. Elevated miR-155 expression induces
immunosuppression via CD39(+) regulatory T-cells in sepsis patient. Int
J Infect Dis 2015; 40:135-41.
130. Flynn S, Eisenstein S. Inflammatory Bowel Disease Presentation and
Diagnosis. Surg Clin North Am 2019; 99:1051-1062.
131. Friedman DJ, Künzli BM, YI AR, et al. From the Cover: CD39 deletion
exacerbates experimental murine colitis and human polymorphisms increase
susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A
2009; 106:16788-93.
132. Huang B, Chen Z, Geng L, et al. Mucosal Profiling of
Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and
Therapeutic Pathways. Cell 2019; 179:1160-1176 e24.
133. Gibson DJ, Elliott L, McDermott E, et al. Heightened Expression of
CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic
Remission in Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;
21:2806-14.
134. Longhi MS, Moss A, Bai A, et al. Characterization of human CD39+
Th17 cells with suppressor activity and modulation in inflammatory bowel
disease. PLoS One 2014; 9:e87956.
135. Doherty GA, Bai A, Hanidziar D, et al. CD73 is a phenotypic marker
of effector memory Th17 cells in inflammatory bowel disease. Eur J
Immunol 2012; 42:3062-72.
136. Kunzli BM, Berberat PO, Dwyer K, et al. Variable impact of CD39 in
experimental murine colitis. Dig Dis Sci 2011; 56:1393-403.
137. Bonner F, Borg N, Burghoff S, Schrader J. Resident cardiac immune
cells and expression of the ectonucleotidase enzymes CD39 and CD73 after
ischemic injury. PLoS One 2012; 7:e34730.
138. Eckle T, Krahn T, Grenz A, et al. Cardioprotection by
ecto-5’-nucleotidase (CD73) and A2B adenosine receptors. Circulation
2007; 115:1581-90.
139. Grenz A, Osswald H, Eckle T, et al. The reno-vascular A2B adenosine
receptor protects the kidney from ischemia. PLoS Med 2008; 5:e137.
140. Kinsey GR, Huang L, Jaworska K, et al. Autocrine adenosine
signaling promotes regulatory T cell-mediated renal protection. J Am Soc
Nephrol 2012; 23:1528-37.
141. Jian R, Sun Y, Wang Y, et al. CD73 protects kidney from
ischemia-reperfusion injury through reduction of free radicals. APMIS
2012; 120:130-8.
142. Hart ML, Gorzolla IC, Schittenhelm J, et al. SP1-dependent
induction of CD39 facilitates hepatic ischemic preconditioning. J
Immunol 2010; 184:4017-24.
143. Sun X, Imai M, Nowak-Machen M, et al. Liver damage and systemic
inflammatory responses are exacerbated by the genetic deletion of CD39
in total hepatic ischemia. Purinergic Signal 2011; 7:427-34.
144. Hart ML, Henn M, Kohler D, et al. Role of extracellular nucleotide
phosphohydrolysis in intestinal ischemia-reperfusion injury. FASEB J
2008; 22:2784-97.
145. Hart ML, Grenz A, Gorzolla IC, et al. Hypoxia-inducible
factor-1alpha-dependent protection from intestinal ischemia/reperfusion
injury involves ecto-5’-nucleotidase (CD73) and the A2B adenosine
receptor. J Immunol 2011; 186:4367-74.
146. Boring YC, Flogel U, Jacoby C, et al. Lack of ecto-5’-nucleotidase
(CD73) promotes arteriogenesis. Cardiovasc Res 2013; 97:88-96.
147. Aldi S, Marino A, Tomita K, et al. E-NTPDase1/CD39 modulates renin
release from heart mast cells during ischemia/reperfusion: a novel
cardioprotective role. FASEB J 2015; 29:61-9.
148. Ziegler M, Hohmann JD, Searle AK, et al. A single-chain
antibody-CD39 fusion protein targeting activated platelets protects from
cardiac ischaemia/reperfusion injury. Eur Heart J 2018; 39:111-116.
149. Sashindranath M, Dwyer KM, Dezfouli S, et al. Development of a
novel strategy to target CD39 antithrombotic activity to the
endothelial-platelet microenvironment in kidney ischemia-reperfusion
injury. Purinergic Signal 2017; 13:259-265.
150. Duan L, Hu GH, Li YJ, et al. P2X7 receptor is involved in lung
injuries induced by ischemia-reperfusion in pulmonary arterial
hypertension rats. Mol Immunol 2018; 101:409-418.
151. Cai M, Huttinger ZM, He H, et al. Transgenic over expression of
ectonucleotide triphosphate diphosphohydrolase-1 protects against murine
myocardial ischemic injury. J Mol Cell Cardiol 2011; 51:927-35.
152. Wheeler DG, Joseph ME, Mahamud SD, et al. Transgenic swine:
expression of human CD39 protects against myocardial injury. J Mol Cell
Cardiol 2012; 52:958-61.
153. Xia N, Jiao J, Tang TT, et al. Activated regulatory T-cells
attenuate myocardial ischaemia/reperfusion injury through a
CD39-dependent mechanism. Clin Sci (Lond) 2015; 128:679-93.
154. Pommey S, Lu B, McRae J, et al. Liver grafts from
CD39-overexpressing rodents are protected from ischemia reperfusion
injury due to reduced numbers of resident CD4+ T cells. Hepatology 2013;
57:1597-606.
155. Ring S, Oliver SJ, Cronstein BN, et al. CD4+CD25+ regulatory T
cells suppress contact hypersensitivity reactions through a CD39,
adenosine-dependent mechanism. J Allergy Clin Immunol 2009; 123:1287-96
e2.
156. Mahnke K, Useliene J, Ring S, et al. Down-Regulation of CD62L
Shedding in T Cells by CD39(+) Regulatory T Cells Leads to Defective
Sensitization in Contact Hypersensitivity Reactions. J Invest Dermatol
2017; 137:106-114.
157. Li P, Gao Y, Cao J, et al. CD39+ regulatory T cells attenuate
allergic airway inflammation. Clin Exp Allergy 2015; 45:1126-37.
158. Li P, Yang QZ, Wang W, et al. Increased IL-4- and IL-17-producing
CD8(+) cells are related to decreased CD39(+)CD4(+)Foxp3(+) cells in
allergic asthma. J Asthma 2018; 55:8-14.
159. Wang LL, Tang HP, Shi GC, et al. CD39/CD73 and the imbalance of
Th17 cells and regulatory T cells in allergic asthma. Mol Med Rep 2013;
8:1432-8.
160. Wang LL, Tang PH, Shi CG, et al. Expression of CD39 mRNA is altered
in the peripheral blood of patients with allergic asthma. Biomed Rep
2014; 2:75-78.
161. Idzko M, C KA, Muller T, et al. Attenuated allergic airway
inflammation in Cd39 null mice. Allergy 2013; 68:472-80.
162. Li P, Cao J, Chen Y, et al. Apyrase protects against allergic
airway inflammation by decreasing the chemotactic migration of dendritic
cells in mice. Int J Mol Med 2014; 34:269-75.
163. Becker LV, Passos DF, Leal DBR, et al. ATP signaling and NTPDase in
Systemic Lupus Erythematosus (SLE). Immunobiology 2019; 224:419-426.
164. Becker LV, da Silva Pereira Saccol R, Morsch VM, et al. Activity
and expression of E-NTPDase is altered in peripheral lymphocytes of
systemic lupus erythematosus patients. Clin Chim Acta 2019; 488:90-97.
165. Loza MJ, Anderson AS, O’Rourke KS, et al. T-cell specific defect in
expression of the NTPDase CD39 as a biomarker for lupus. Cell Immunol
2011; 271:110-7.
166. Akesson K, Tompa A, Ryden A, Faresjo M. Low expression of CD39(+)
/CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic
children in contrast to high expression of CD101(+) /CD129(+) on Treg
cells in children with coeliac disease. Clin Exp Immunol 2015;
180:70-82.
167. Jin X, Zhang C, Gong L, et al. Altered expression of CD39 on memory
regulatory T cells in type 1 diabetes patients. J Diabetes 2019;
11:440-448.
168. Garcia-Hernandez MH, Portales-Cervantes L, Cortez-Espinosa N, et
al. Expression and function of P2X(7) receptor and CD39/Entpd1 in
patients with type 2 diabetes and their association with biochemical
parameters. Cell Immunol 2011; 269:135-43.
169. Cortez-Espinosa N, Cortes-Garcia JD, Martinez-Leija E, et al. CD39
expression on Treg and Th17 cells is associated with metabolic factors
in patients with type 2 diabetes. Hum Immunol 2015; 76:622-30.
170. Zhang W, Zhou L, Dang J, et al. Human Gingiva-Derived Mesenchymal
Stem Cells Ameliorate Streptozoticin-induced T1DM in mice via
Suppression of T effector cells and Up-regulating Treg Subsets. Sci Rep
2017; 7:15249.
171. Chia JS, McRae JL, Thomas HE, et al. The protective effects of CD39
overexpression in multiple low-dose streptozotocin-induced diabetes in
mice. Diabetes 2013; 62:2026-35.
172. Mandapathil M, Boduc M, Roessler M, et al. Ectonucleotidase CD39
expression in regional metastases in head and neck cancer. Acta
Otolaryngol 2018; 138:428-432.
173. Mandapathil M, Szczepanski MJ, Szajnik M, et al. Increased
ectonucleotidase expression and activity in regulatory T cells of
patients with head and neck cancer. Clin Cancer Res 2009; 15:6348-57.
174. Pulte D, Furman RR, Broekman MJ, et al. CD39 expression on T
lymphocytes correlates with severity of disease in patients with chronic
lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2011; 11:367-72.
175. Cai XY, Wang XF, Li J, et al. High expression of CD39 in gastric
cancer reduces patient outcome following radical resection. Oncol Lett
2016; 12:4080-4086.
176. Cai X-Y, Wang X-F, Li J, et al. Overexpression of CD39 and high
tumoral CD39⁺/CD8⁺ ratio are associated with adverse prognosis in
resectable gastric cancer. International journal of clinical and
experimental pathology 2015; 8:14757-14764.
177. Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J
Immunother Cancer 2018; 6:57.
178. Cai XY, Ni XC, Yi Y, et al. Overexpression of CD39 in
hepatocellular carcinoma is an independent indicator of poor outcome
after radical resection. Medicine (Baltimore) 2016; 95:e4989.
179. Parodi A, Battaglia F, Kalli F, et al. CD39 is highly involved in
mediating the suppression activity of tumor-infiltrating CD8+ T
regulatory lymphocytes. Cancer Immunol Immunother 2013; 62:851-62.
180. Sundström P, Stenstad H, Langenes V, et al. Regulatory T Cells from
Colon Cancer Patients Inhibit Effector T-cell Migration through an
Adenosine-Dependent Mechanism. Cancer Immunol Res 2016; 4:183-93.
181. Retseck J, Nasr A, Lin Y, et al. Long term impact of CTLA4 blockade
immunotherapy on regulatory and effector immune responses in patients
with melanoma. 2018; 16:184.
182. Zheng Y, Li Y, Tang B, et al. IL-6-induced CD39 expression on
tumor-infiltrating NK cells predicts poor prognosis in esophageal
squamous cell carcinoma. Cancer Immunol Immunother 2020.
183. Yin Z, Li C, Wang J, Xue L. Myeloid-derived suppressor cells: Roles
in the tumor microenvironment and tumor radiotherapy. Int J Cancer 2019;
144:933-946.
184. Li J, Wang L, Chen X, et al. CD39/CD73 up-regulation on
myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in
patients with non-small cell lung cancer. Oncoimmunology 2017; 6:00-00.
185. Limagne E, Euvrard R, Thibaudin M, et al. Accumulation of MDSC and
Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the
Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen. Cancer Res
2016; 76:5241-52.
186. Li L, Wang L, Li J, et al. Metformin-Induced Reduction of CD39 and
CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with
Ovarian Cancer. Cancer Res 2018; 78:1779-1791.
187. Sun X, Wu Y, Gao W, et al. CD39/ENTPD1 expression by CD4+Foxp3+
regulatory T cells promotes hepatic metastatic tumor growth in mice.
Gastroenterology 2010; 139:1030-40.
188. Jackson SW, Hoshi T, Wu Y, et al. Disordered purinergic signaling
inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am J Pathol
2007; 171:1395-404.
189. Sun X, Han L, Seth P, et al. Disordered purinergic signaling and
abnormal cellular metabolism are associated with development of liver
cancer in Cd39/ENTPD1 null mice. Hepatology 2013; 57:205-16.
190. Künzli BM, Rath S, Käser S, et al. Impact of CD39 and purinergic
signalling on the growth and metastasis of colorectal cancer. Purinergic
Signalling 2011; 7:231-241.
191. Bastid J, Regairaz A, Bonnefoy N, et al. Inhibition of CD39
enzymatic function at the surface of tumor cells alleviates their
immunosuppressive activity. Cancer immunology research 2015; 3:254-265.
192. Li XY, Moesta AK, Xiao C, et al. Targeting CD39 in Cancer Reveals
an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. Cancer
Discov 2019; 9:1754-1773.